Skip to content
AnalystLens

Welltower 8-K Report, Financial Results (Oct 27, 2025)

Reports
Earnings & Results·Regulation FD·Exhibits & Filings
Filing Date
Filed October 27, 2025
Period End
October 27, 2025
Security
WELL
In the record · 2016–202610-K1110-Q338-K160

WELL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 160 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Jul ’18Jul ’18
  2. Leadership change8-K · Apr ’20Apr ’20
  3. Material agreement8-K · Jun ’22Jun ’22
  4. Leadership change8-K · Jan ’25Jan ’25

Summary

Summary of the 8-K filed October 27, 2025. Cited figures are marked; the original filing is the authoritative source.

Welltower (NYSE: WELL) reported third quarter 2025 results on October 27, 2025, with normalized FFO of $1.34a per diluted share, up 20.7% year over year, and total portfolio same store NOI growth of 14.5%, led by a 20.3% increase in the Seniors Housing Operating (SHO) portfolio.

SHO same store margin expanded 260 bps on 9.7% revenue growth, driven by roughly 400 bps of occupancy gains and 4.8% RevPOR growth. GAAP net income attributable to common stockholders was $0.41b per diluted share, versus $0.73 a year earlier, largely reflecting the lapping of prior-year gains on dispositions. Alongside results, the company announced roughly $23 billion of transaction activity closed or under contract.

The centerpiece is a £5.2 billion acquisition of a U.K. portfolio operated by Barchester, plus the £1.2 billion HC-One equity acquisition (funded in part by repaying a £660 million loan) and about $4 billionc of additional seniors housing deals. These are offset by a definitive agreement to sell an 18 million sq ft outpatient medical portfolio for about $7.2 billion, with the first $2 billion tranche closed in October 2025. Management says the acquisitions are fully funded through dispositions, loan payoffs, and capital raising, and that the company's net debt to Adjusted EBITDA was 2.36x at quarter end, with about $11.9 billion of liquidity.

Full-year 2025 normalized FFO guidance was raised to $5.24d–$5.30 per diluted share from $5.06–$5.14, while GAAP net income guidance was cut sharply to $0.82–$0.88 from $1.86–$1.94, reflecting the impact of the new Ten Year Executive Continuity and Alignment Program (about $1.08 billion of expected stock compensation). Investors should note that guidance includes only transactions announced to date, and that the GAAP-to-normalized FFO gap is large this year. The company also declared a $0.74 quarterly dividend, its 218th consecutive quarterly payment.

Key Highlights

  1. Q3 2025 normalized FFO of $1.34 per diluted share, up 20.7% year over year; GAAP net income of $0.41 per diluted share, down from $0.73.
  2. Total portfolio same store NOI grew 14.5%, with SHO same store NOI up 20.3% and SHO same store margin expanded 260 bps to a 29.9% level.
  3. Announced about $23 billion of transactions closed or under contract, including £5.2 billion Barchester UK portfolio and £1.2 billion HC-One acquisition.
  4. Agreed to sell an 18M sq ft outpatient medical portfolio for about $7.2 billion; first $2 billion tranche closed in October 2025, with remaining tranches through mid-2026.
  5. Raised 2025 normalized FFO guidance to $5.24–$5.30 per diluted share, but cut GAAP net income guidance to $0.82–$0.88 due to the executive compensation program.
  6. Net debt to Adjusted EBITDA of 2.36x and approximately $11.9 billion of available liquidity as of September 30, 2025.
  7. Declared a $0.74 quarterly dividend (218th consecutive), payable November 20, 2025 to holders of record on November 11, 2025.

Frequently Asked Questions

  1. Why did GAAP net income guidance fall so sharply while normalized FFO guidance rose?

    The revised GAAP net income outlook of $0.82–$0.88 per diluted share reflects about $1.08 billion of expected stock compensation tied to the Ten Year Executive Continuity and Alignment Program, along with net impairments and gains in the disposition activity. Normalized FFO excludes these items, so it rose to $5.24–$5.30 on stronger operating performance and the benefit of the Q3 SHO growth.

  2. How is Welltower funding the roughly $23 billion of announced transactions?

    Management says acquisitions are funded through about $9 billion of pro rata dispositions and loan repayments, including the $7.2 billion outpatient medical sale and $1.8 billion of expected loan proceeds, along with cash on hand and capital raised during Q3. Guidance assumes a blended disposition yield of 7.1%.

  3. What is driving the strong same store NOI growth?

    The SHO portfolio drove most of the growth, with 20.3% same store NOI growth. Average occupancy rose about 400 bps year over year, and RevPOR grew 4.8%. Same store expense growth was held down, which supported the 260 bps margin expansion.

  4. Does the company's leverage position remain manageable after these deals?

    As of September 30, 2025, net debt to Adjusted EBITDA was 2.36x, and net debt to consolidated enterprise value was 7.6%, down from 13.1% a year earlier. Variable rate debt was about 11.3% of the company's share, and management states that acquisitions under contract are fully funded.

  5. What does the outpatient medical sale mean for the portfolio's future mix?

    The sale is expected to be completed in multiple tranches through mid-2026. Welltower will retain a preferred equity interest and profits interest in the sold portfolio, and it will exit the outpatient medical property management business, leaving its retained OM assets mostly on long-term triple-net leases. The company says the announced transactions will raise the seniors housing share of in-place NOI to the mid-80% range.